Navigation Links
Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
Date:11/11/2009

immune system against cancer. PROVENGE and other ACIs are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer.

PROVENGE is being studied in several ongoing clinical trials, including OpenACT, an open label trial enrolling men with metastatic castrate-resistant prostate cancer, ProACT (PROstate cancer Active Cellular immunoTherapy), and NeoACT (NEOadjuvant Active Cellular immunotherapy). For more information regarding these studies, visit www.clinicaltrials.gov.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce ACI product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington, and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects; risks and uncertainties surrounding the presentation of data to the FDA and approval of biologics product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeuti
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Completes Submission of Biologics License Application for PROVENGE
2. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
3. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
4. Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
5. Dendreon Reports Second Quarter 2009 Financial Results
6. Dendreon Signs Lease for New Manufacturing Facility in Atlanta
7. Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET
8. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
9. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
10. Dendreon Announces Closing of Common Stock Offering
11. Dendreon Announces Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... NORTH CHICAGO, Ill. , May 26, 2015 ... biopharmaceutical company, announced today that it has completed ... and commercial presence in oncology. Pharmacyclics is a ... (ibrutinib), a first-in-class BTK-inhibitor used to treat hematological ... "The companies, shared expertise, combined with AbbVie,s broad ...
(Date:5/25/2015)... a science-driven healthcare company seeking to solve some of ... that Dame Marjorie Scardino , Chairman of the ... appointed to PureTech,s Board of Directors in the role ... Joi Ito , MIT Media Lab,s Director, has ... PureTech,s outgoing Chairman and co-founder, former Executive Vice President ...
(Date:5/22/2015)... DUBLIN , May 22, 2015  Actavis plc ... of the U.S. Court of Appeals for the Second ... 2014 preliminary injunction requiring the Company to continue distribution ... Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO   ... uphold this ruling, we intend to continue our strong ...
(Date:5/22/2015)... -- Baylor Research Institute (BRI) at ... (TGen) in Phoenix, AZ , today ... and treatments for patients with a broad range of cancers. ... new clinical trials and access to technology to drive the ... to bedside across Baylor Scott & White Health,s ...
Breaking Biology Technology:AbbVie Completes Acquisition of Pharmacyclics 2AbbVie Completes Acquisition of Pharmacyclics 3AbbVie Completes Acquisition of Pharmacyclics 4AbbVie Completes Acquisition of Pharmacyclics 5AbbVie Completes Acquisition of Pharmacyclics 6PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team 2PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 2Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 4Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 5Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 6Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 7Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 8Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4
... Jeff Cunningham and Lynn Jordan , ... Massachusetts, USA , Introduction ... is an optional accessory to the Sciclone Advanced Liquid Handler (ALH). This ... wells or columns of 96 and 384 well microplates for purposes of ...
... Geoffrey Grove, Ed Alderman Applied Science and ... Monica Adams, Jason Brennan Development Integration, ... Overview , ... Kit is designed to eliminate the requirement for extended bacterial growth ...
... Rudy Willebrords 1 and Bart Moyson 2 , ... & Development, a division of Janssen Pharmaceutica N.V., Laboratory of Virology, Beerse, Belgium ... Caliper Life Sciences Benelux NV, Teralfene, Belgium , ... purpose of this paper is to report the performance obtained by dispensing 1μL ...
Cached Biology Technology:Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 2Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 3Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 4Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 5Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 2Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 3Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 4Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 5Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 696 Well Pipetting Precision Testing Using the Sciclone ALH with a 384 Fixed-Cannula Array 296 Well Pipetting Precision Testing Using the Sciclone ALH with a 384 Fixed-Cannula Array 3
(Date:5/25/2015)... 2015  Australia,s market for wearable technologies is considered ... the advent of several trials and prototypes. The release ... expected to ignite interest in wearables as well as ... . This in turn will spur greater innovation ... partnerships amongst vendors and distributors. Photo ...
(Date:5/22/2015)... According to a new market research report ... by Software (Middleware, Databases), by Hardware (Cameras, Integrated Devices), ... - Global Forecast to 2020", published by MarketsandMarkets, Facial ... to $6.19 Billion by 2020, at a CAGR of ... and   43 Figures spread through 140 Pages and ...
(Date:5/21/2015)... The Sync Project™ , a global collaboration harnessing ... a collaborative partnership with Berklee,s Institute for Creative ... on original research, joint course development and an internship ... Sync Project and BerkleeICE are exploring the launch of ... academic year.  The course will focus ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3
... , , , , , ... AUDIO: Plants capable of producing oils for industrial chemicals and human health are ... Click here for more information. , , , ... , , , , , ...
... de-acetylase (HDAC) inhibitor panobinostat is able to target and ... published in BioMed Central,s open access journal Breast ... Center have shown that panobinostat was able to destroy ... Approximately 15% of breast cancers are found at ...
... Barcelona, 20 May 2012. The Stem Cells and Cancer ... the Vall d,Hebrn Institute of Oncology (VHIO) has identified ... drugs used in clinical trials for colon cancer treatment. ... collaboration with Professor Alberto Muozs laboratory at the Instituto ...
Cached Biology News:Supercharged safflower 2Supercharged safflower 3Supercharged safflower 4Blocking DNA: HDAC inhibitor targets triple negative breast cancer 2Discovery of mechanisms predicting response to new treatments in colon cancer 2Discovery of mechanisms predicting response to new treatments in colon cancer 3
... Large T antigen initiates replication ... replication in the presence of ... product can be used in ... Replication Kit cat. no. 8050. ...
NuParaffin Kit Application: Flow Cytometry Reactivity: Human...
Request Info...
...
Biology Products: